ReviewJournal of the American Society of Nephrology : JASN2017
A Proposal for a Serology-Based Approach to Membranous Nephropathy.
Review in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 3 syntheses or guidelines pooled it, 365 citations in OpenAlex.
- Comparative efficacy and safety of rituximab versus cyclophosphamide with steroids in primary membranous nephropathy: a systematic review and meta-analysis.BMC nephrology · 2026Pooled it
- Prevalence and prognosis of malignancy in THSD7A-associated membranous nephropathy: a systematic literature review and clinical case study.Renal failure · 2024Pooled it
- Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis.International journal of clinical practice · 2022Pooled it
- A preliminary nomogram model for predicting relapse of patients with primary membranous nephropathy.Renal failure · 2023Trial
- High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2019Trial
- FAT1-associated membranous nephropathy after hematopoietic stem cell transplantation: a case report and review of the literature.CEN case reports · 2026Review
- Comparison of efficacy and safety among four therapeutic regimens in primary membranous nephropathy with high anti-PLA2R antibody titers: a single-center retrospective cohort study.BMC nephrology · 2026Article
- Optimization of a Target Antigen Diagnostic Pathway for Membranous Nephropathy.Kidney international reports · 2026Article
- Multiplexed Detection of Membranous Nephropathy Antigens by Multi-Reaction Monitoring Mass Spectrometry.Kidney international reports · 2026Article
- Serum anti-PLA2R negativity does not exclude glomerular PLA2R expression in primary membranous nephropathy.Biomolecules & biomedicine · 2026Article
- Mechanisms of Podocyte Injury in Kidney Allografts.Kidney360 · 2026Review
- Comparison of the efficacy of obinutuzumab versus rituximab combined with tacrolimus in the treatment of refractory membranous nephropathy.BMC nephrology · 2026Article
- Clinical profile and outcome of primary membranous nephropathy: A tertiary care center experience from North India.World journal of nephrology · 2026Article
- Obinutuzumab Versus Rituximab for the Treatment of Primary Membranous Nephropathy: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2026Review
- Repeat kidney biopsy in patients with ANCA-associated vasculitis and suspected kidney relapse.Clinical kidney journal · 2026Article
- How to Cure Autoimmune GN and Podocytopathies.Journal of the American Society of Nephrology : JASN · 2026Review
- Article
- Earlier Hematuria Negative Conversion Was an Independent Predictor for Nephrotic Remission in Patients with Primary Membranous Nephropathy and Nephrotic Syndrome.American journal of nephrology · 2026Article
- Exploring causality between peripheral blood B cell subtypes and membranous nephropathy: a two-sample Mendelian randomization study.Archives of medical science : AMS · 2026Article
- From immune dysregulation to renal injury: mechanistic insights and translational opportunities in immune-mediated nephropathies.Frontiers in cell and developmental biology · 2026Review
122 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary membranous nephropathy (MN) is an autoimmune disease mainly caused by autoantibodies against the recently discovered podocyte antigens: the M-type phospholipase A2 receptor 1 (PLA2R) and thrombospondin type 1 domain-containing 7A (THSD7A). Assays for quantitative assessment of anti-PLA2R antibodies are commercially available, but a semiquantitative test to detect anti-THSD7A antibodies has been only recently developed. The presence or absence of anti-PLA2R and anti-THSD7A antibodies adds important information to clinical and immunopathologic data in discriminating between primary and secondary MN. Levels of anti-PLA2R antibodies and possibly, anti-THSD7A antibodies tightly correlate with disease activity. Low baseline and decreasing anti-PLA2R antibody levels strongly predict spontaneous remission, thus favoring conservative therapy. Conversely, high baseline or increasing anti-PLA2R antibody levels associate with nephrotic syndrome and progressive loss of kidney function, thereby encouraging prompt initiation of immunosuppressive therapy. Serum anti-PLA2R antibody profiles reliably predict response to therapy, and levels at completion of therapy may forecast long-term outcome. Re-emergence of or increase in antibody titers precedes a clinical relapse. Persistence or reappearance of anti-PLA2R antibodies after kidney transplant predicts development of recurrent disease. We propose that an individualized serology-based approach to MN, used to complement and refine the traditional proteinuria-driven approach, will improve the outcome in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.